What’s Going On With Black Diamond Therapeutics Stock Tuesday?

by | May 26, 2026 | General

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) stock climbed in Tuesday’s session.

The company recently reported encouraging Phase 2 data for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations.

The clinical-stage oncology company said the Phase 2 results support silevertinib’s potential as a practice-changing treatment for NSCLC patients with EGFR non-classical mutations, with promising preliminary progression-free survival data. The findings are scheduled to be presented at the ASCO Annual Meeting on May 30, 2026.

Black Diamond Therapeutics Earnings Snapshot

Earlier this month, Black Diamond Therapeutics reported a first-quarter loss of 16 cents per share, beating Wall Street estimates for a loss of 18 cents per share.

Research and development expenses declined to $7 million from $10.5 million a year ago, primarily due to progress in the Phase 2 silevertinib NSCLC trial and the outlicensing of BDTX-4933 as the company sharpened its focus on silevertinib development.

As of March 31, 2026, the company held $118.3 million in cash, cash equivalents and investments, which management said is expected to fund operations into the second half of 2028.

BDTX Technical Analysis: Trend, Moving Averages And Momentum

Currently, BDTX is trading at $2.36. This places it 16.2% below its 20-day simple moving average (SMA) of $2.84 and 9.7% below its 50-day SMA of $2.63. The stock has seen a 12-month performance of 11.22%, indicating some resilience over the longer term despite recent volatility.

The moving averages present a mixed picture. While the 20-day SMA is above the 50-day SMA, indicating a bullish short-term trend, the 50-day SMA is below the 200-day SMA, signaling a death cross that could suggest longer-term bearish sentiment.

For momentum analysis, the MACD is currently below its signal line, indicating that momentum is fading, which could suggest caution for traders looking for upward movement.

What Black Diamond Therapeutics (BDTX) Does

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer.

The foundation of the company has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.

Its clinical-stage program, silevertinib (formerly BDTX-1535), is currently being studied in a Phase 2 clinical trial in patients with EGFR mutant non-small cell lung cancer (NSCLC).

Analyst Consensus & Recent Actions

The stock carries a Buy rating with an average price forecast of $11.00. Recent analyst moves include:

  • BTIG: Buy (Raises forecast to $11.00) (April 29)
  • Wedbush: Outperform (Raises forecast to $14.00) (March 17)
  • Piper Sandler: Overweight (Lowers forecast to $8.00) (January 16)

Black Diamond Therapeutics Price Action

BDTX Stock Price Activity: Black Diamond Therapeutics shares were up 3.51% at $2.36 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo via ShutterstockÂ